Intentar ORO - Gratis
Focusing on VIGILANCE & PREPAREDNESS
BioSpectrum Asia
|BioSpectrum Asia Dec 2021
Despite advances in development of countermeasures such as diagnostics, therapeutics and vaccines, world travel and increased global interdependence have added layers of complexity to containing infectious diseases.
COVID-19, an outcome of weaponisation by genetic manipulation as part of ‘gain of function’ research, had brought the entire world to its knees in less than six months. Now, researchers and policymakers are being more vigilant towards surveillance and management of emerging infectious disease threats, and revisit global mechanisms for the control of pandemic disease. In addition to other countries across the globe, 2021 saw many initiatives taken by the APAC region to strengthen their capacities for effective preparedness and for the prevention of new and existing infectious diseases.
Infectious diseases have been increasing in frequency during the past few decades. These include recurring outbreaks caused by influenza and Ebola viruses; diseases that have dramatically increased their range and impact such as Chikungunya and Zika viruses; and outbreaks caused by novel pathogens such as severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) in 2002 and SARS-CoV-2 in 2019–20, the virus responsible for the current COVID-19 pandemic.
A section of experts attribute this to unlawful and potentially dangerous ‘gain of function’ research which, among other reasons, looks to ‘weaponise’ the naturally occurring viruses. More recently, Bill Gates announced the successful development of a vaccine against smallpox (a disease already eradicated) in the (un)likely event of a bioterror attack using the smallpox virus. The unprecedented scale and rapidity of dissemination of recent emerging infectious diseases pose new challenges for vaccine developers, regulators, health authorities and political constituencies.
Esta historia es de la edición BioSpectrum Asia Dec 2021 de BioSpectrum Asia.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE BioSpectrum Asia
BioSpectrum Asia
Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries
Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Biotium launches GlycoLiner Cell Surface Glycoprotein Labeling Kits
US-based Biotium, a leading innovator in fluorescent dyes and life science reagents, has announced the launch of GlycoLiner Cell Surface Glycoprotein Labeling Kits for rapid, selective, and covalent labeling of cell surface glycoproteins.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO
Australia-based Vaxxas has announced the appointment of global biopharmaceutical executive David Peacock as Chief Executive Officer (CEO) to lead the commercialisation of the company's proprietary high-density microarray patch (HD-MAP) vaccination technology.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Thermo Fisher partners with NVIDIA leveraging AI to advance scientific instrumentation
US-based Thermo Fisher Scientific Inc. has announced a strategic collaboration with NVIDIA to power artificial intelligence (AI)based solutions and laboratory automation at scale.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Bruker consolidates ownership of TOFWERK in expansion of mass spectrometry portfolio
Bruker Corporation has announced the acquisition of an additional 60 per cent ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker's ownership to 100 per cent.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Bioengineered tissue by Japan emerges as revolutionary treatment for secondary lymphedema
A research team led by Associate Professor Kosuke Kusamori from the Faculty of Pharmaceutical Sciences at Tokyo University of Science (TUS), Japan, is pioneering an innovative technique for lymphatic tissue engineering that could revolutionize the treatment of secondary lymphedema.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Chitose and Fujifilm Biosciences to drive global innovation and biopharma manufacturing
Japan-based Chitose Laboratory Corp. & Fujifilm Biosciences Inc. have announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Vibrant Therapeutics on-boards Dr Han Lee as Co-CEO
Vibrant Therapeutics, a clinical-stage biotechnology company based in China and US, has announced the appointment of Dr Han Lee as co-chief executive officer (CEO).
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
IIT-D and AIIMS develop swallowable microdevice for microbiome study
Researchers at the Indian Institute of Technology (IIT) Delhi, and All India Institute of Medical Sciences (AIIMS) have developed an ingestible device that can sample bacteria directly from the small intestine, opening a new window into the human gut microbiome.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Ambitious research to develop multivalent vaccines against multiple deadly filoviruses
Scientists at the University of Oxford, in collaboration with partners, will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus.
1 min
BioSpectrum Asia Feb 2026
Translate
Change font size
